Results of a recent drug trial suggest that premenopausal women with hypoactive sexual desire disorder (HSDD) may benefit from a daily dose of flibanserin, a medication designed to improve sexual desire.
Flibanserin Treatment Increases Appetitive Sexual Motivation in the Female Rat
The drug flibanserin is currently in clinical trials for the treatment of HSDD and is showing some encouraging results in premenopausal women, including improved sexual desire and an increase in the number of satisfying sexual events. The current study aimed to investigate how acute and chronic doses of flibanserin affected sexual behavior in ovariectomized (OVX) female rats who have been primed with either a combination of estradiol benzoate (EB) and progesterone (P) [Experiment 1] or estradiol benzoate (EB) alone [Experiment 2].